Vanta Bioscience Ltd Stock Price Today (NSE: VANTABIO)
Vanta Bioscience Ltd
Fundamental Score
Vanta Bioscience Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Vanta Bioscience Ltd share price today is ₹15.15, down 10.72% on NSE/BSE as of 30 March 2026. Vanta Bioscience Ltd (VANTABIO) is a Small-cap company in the Healthcare Research, Analytics & Technology sector with a market capitalisation of ₹16.84 (Cr). The 52-week high for VANTABIO share price is ₹31.33 and the 52-week low is ₹14.71. The company has a Return on Equity (ROE) of -37.24% and a debt-to-equity ratio of 1.59.
Vanta Bioscience Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Vanta Bioscience Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Vanta Bioscience Share Price: A Risk Management Perspective
The healthcare research, analytics, and technology sector is currently witnessing a surge in demand for specialized contract research organizations (CROs), driven by pharmaceutical companies seeking to streamline drug development processes and reduce costs. This analysis focuses on Vanta Bioscience share price (₹19.5), offering a risk management perspective based on publicly available financial data. This is part of an 80-parameter fundamental audit, verified by Sweta Mishra, and solely provides an observational analysis, not a recommendation to buy or sell.
A crucial element of this risk assessment is the company's profitability, or lack thereof, as highlighted by its Return on Capital Employed (ROCE) of -11.58%. This negative ROCE indicates that Vanta Bioscience is currently destroying value with the capital it employs. In contrast to
NOVELIX PHARMACEUTICALS LIMITE, whose management team has demonstrated consistent improvement in operational efficiency, Vanta Bioscience's negative ROCE raises questions about its operational effectiveness and strategic direction.The absence of a Price-to-Earnings (PE) ratio further underscores the company's current lack of profitability. This missing metric prevents a standard valuation comparison with sector peers such as Suven Life Sciences Ltd and Syngene International Ltd. While these peers may have their own challenges, the lack of earnings for Vanta Bioscience presents a significantly higher risk profile for potential investors. A sustainable competitive advantage, or "moat," is often built on superior financial performance. A consistently negative ROCE of -11.58% significantly erodes any potential moat, making it difficult for Vanta Bioscience to generate sustainable profits and attract investor confidence.
Therefore, the negative ROCE raises concerns about the long-term financial stability of Vanta Bioscience and its ability to compete effectively within the CRO sector. Further investigation into the underlying reasons for this negative performance, including cost structure, revenue generation, and capital allocation, is warranted to fully assess the risks associated with Vanta Bioscience share price.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Vanta Bioscience Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of VANTABIO across key market metrics for learning purposes.
Positive Indicators
2 factors identified
Balanced Promoter Holding (72.81%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
8 factors identified
Below-Average Return on Equity (-37.24%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (-11.58%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Revenue Contraction (-70.87%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Limited Growth History (-32.27% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Elevated Debt Levels (D/E: 1.59)
Observation: High leverage increases financial risk and interest burden.
Analysis: High debt-to-equity ratios require monitoring of debt servicing capability.
Weak Interest Coverage (-2.69x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Negative Free Cash Flow (₹-43.40 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Vanta Bioscience Ltd Financial Statements
Comprehensive financial data for Vanta Bioscience Ltd including income statement, balance sheet and cash flow
About VANTABIO (Vanta Bioscience Ltd)
Vanta Bioscience Ltd is a cutting-edge healthcare research organization dedicated to accelerating drug discovery and development through advanced analytics and innovative technolog...ies. We provide comprehensive preclinical research services, leveraging state-of-the-art facilities and a team of expert scientists to deliver robust and reliable data. Our expertise spans a wide range of disciplines, including molecular biology, pharmacology, toxicology, and bioanalysis. By integrating sophisticated analytical tools with deep scientific knowledge, we empower our clients to make informed decisions, optimize their research strategies, and ultimately bring life-changing therapies to market faster. At Vanta Bioscience, we are committed to delivering excellence at every stage of the preclinical research process. Our services include specialized assay development, validation, and execution of in vitro and in vivo studies, tailored to meet the unique needs of our clients. We utilize advanced techniques such as genomics, proteomics, and metabolomics to gain deeper insights into disease mechanisms and drug action. Furthermore, we offer comprehensive regulatory support, ensuring compliance with international guidelines and standards. Our goal is to be a trusted partner for pharmaceutical, biotechnology, and agrochemical companies, enabling them to overcome scientific challenges and achieve their research goals. Vanta Bioscience leverages its unique combination of scientific expertise, technological innovation, and rigorous quality control to provide actionable insights for our clients. We believe in the power of data-driven decision-making and continually invest in cutting-edge technologies to enhance our capabilities. From target identification to lead optimization, we offer a complete suite of services to support the entire preclinical drug development pipeline. By partnering with Vanta Bioscience, our clients gain access to a world-class research team, advanced analytical tools, and a commitment to delivering high-quality results that accelerate the development of innovative healthcare solutions.
Company Details
Key Leadership
VANTABIO Share Price: Frequently Asked Questions
What is the current share price of Vanta Bioscience Ltd (VANTABIO)?
As of 30 Mar 2026, 12:07 pm IST, Vanta Bioscience Ltd share price is ₹15.15. The VANTABIO stock has a market capitalisation of ₹16.84 (Cr) on NSE/BSE.
Is VANTABIO share price Overvalued or Undervalued?
VANTABIO share price is currently trading at a P/E ratio of 0.00x, compared to the industry average of 45.95x. Based on this relative valuation, the Vanta Bioscience Ltd stock appears to be Fairly Valued against its sector peers.
What is the 52-week high and low of VANTABIO share price?
The 52-week high of VANTABIO share price is ₹31.33 and the 52-week low is ₹14.71. These values are updated daily from NSE/BSE price data.
What factors affect the Vanta Bioscience Ltd share price?
Key factors influencing VANTABIO share price include quarterly earnings growth (Sales Growth: -70.87%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Vanta Bioscience Ltd a good stock for long-term investment?
Vanta Bioscience Ltd shows a 5-year Profit Growth of N/A% and an ROE of -37.24%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 1.59 before investing in VANTABIO shares.
How does Vanta Bioscience Ltd compare with its industry peers?
Vanta Bioscience Ltd competes with major peers in the Healthcare Research, Analytics & Technology. Investors should compare VANTABIO share price P/E of 0.00x and ROE of -37.24% against the industry averages to determine competitive standing.
What is the P/E ratio of VANTABIO and what does it mean?
VANTABIO share price has a P/E ratio of N/Ax compared to the industry average of 45.95x. Investors pay ₹N/A for every ₹1 of annual earnings.
How is VANTABIO performing according to Bull Run's analysis?
VANTABIO has a Bull Run fundamental score of 7.2/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does VANTABIO belong to?
VANTABIO operates in the Healthcare Research, Analytics & Technology industry. This classification helps understand the competitive landscape and sector-specific trends affecting Vanta Bioscience Ltd share price.
What is Return on Equity (ROE) and why is it important for VANTABIO?
VANTABIO has an ROE of -37.24%, which suggests challenges in generating returns from shareholders equity. ROE measures how efficiently Vanta Bioscience Ltd generates profits from shareholders capital.
How is VANTABIO debt-to-equity ratio and what does it indicate?
VANTABIO has a debt-to-equity ratio of 1.59, which indicates high leverage that increases financial risk.
What is VANTABIO dividend yield and is it a good dividend stock?
VANTABIO offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Vanta Bioscience Ltd shares.
How has VANTABIO share price grown over the past 5 years?
VANTABIO has achieved 5-year growth rates of: Sales Growth -32.27%, Profit Growth N/A%, and EPS Growth N/A%.
What is the promoter holding in VANTABIO and why does it matter?
Promoters hold 72.81% of VANTABIO shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Vanta Bioscience Ltd.
What is VANTABIO market capitalisation category?
VANTABIO has a market capitalisation of ₹17 crores, placing it in the Small-cap category.
How volatile is VANTABIO stock?
VANTABIO has a beta of N/A. A beta > 1 suggests the Vanta Bioscience Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is VANTABIO operating profit margin trend?
VANTABIO has a 5-year average Operating Profit Margin (OPM) of 5.69%, indicating the company's operational efficiency.
How is VANTABIO quarterly performance?
Recent quarterly performance shows Vanta Bioscience Ltd YoY Sales Growth of -70.87% and YoY Profit Growth of 12.08%.
What is the institutional holding pattern in VANTABIO?
VANTABIO has FII holding of 0.00% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the Vanta Bioscience Ltd stock.